Boundless Bio Starts $100 Million U.S. IPO Plan [Seeking Alpha]
Fate Therapeutics, Inc. (FATE)
Last fate therapeutics, inc. earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fatetherapeutics.com/investor-relations
Company Research
Source: Seeking Alpha
The firm's lead candidate, BBI-355, is in Phase 1 trials for the treatment of oncogene amplified cancers. The global market for solid tumor cancer treatments is forecasted to reach $532 billion by 2032, providing a large addressable market for Boundless Bio's technologies. The likely valuation of the company at IPO is in the range of $250 million to $500 million. I'll provide an update when we learn more information. Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Learn More » A Quick Take On Boundless Bio, Inc. Boundless Bio, Inc. BOLD ) has filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration statement , although the final figure may vary. The firm is a clinical stage biopharma developing DNA treatments for various cancers. Boundless has a potentially large addressable market for its technologies, but also faces substantial competition from direct competitors as well as other treatment appr
Show less
Read more
Impact Snapshot
Event Time:
FATE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FATE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FATE alerts
High impacting Fate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FATE
News
- Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.MarketBeat
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual MeetingGlobeNewswire
- Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress [Yahoo! Finance]Yahoo! Finance
FATE
Earnings
- 2/26/24 - Beat
FATE
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- FATE's page on the SEC website